CIK 0001549595
- Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 270838048
- Phone
- +1 415-660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 1 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-08 | Beaurang Pierre Chief Business Officer | Sale | −2,810 | $36.48 | $103K | 4,690 |
| 2021-03-08 | Beaurang Pierre Chief Business Officer | Sale | −4,490 | $37.31 | $168K | 200 |
| 2021-03-08 | Beaurang Pierre Chief Business Officer | Sale | −200 | $38.34 | $8K | 0 |
| 2021-03-08 | Beaurang Pierre Chief Business Officer | Exercise or conversion · Employee Stock Option (right to buy) | −7,500 | 6,726 | ||
| 2021-03-01 | Hansen Gwenn Chief Scientific Officer | Exercise or conversion | +800 | $7.26 | $6K | 14,604 |
| 2021-03-01 | Hansen Gwenn Chief Scientific Officer | Sale | −800 | $35.95 | $29K | 13,804 |
| 2021-03-01 | Hansen Gwenn Chief Scientific Officer | Exercise or conversion · Employee Stock Option (right to buy) | −800 | 75,066 | ||
| 2021-02-24 | van Houte Hans Chief Financial Officer | Exercise or conversion | +20,393 | $1.20 | $24K | 20,393 |
| 2021-02-24 | van Houte Hans Chief Financial Officer | Exercise or conversion | +13,197 | $1.86 | $25K | 33,590 |
| 2021-02-24 | van Houte Hans Chief Financial Officer | Exercise or conversion | +1,829 | $7.26 | $13K | 35,419 |
| 2021-02-24 | van Houte Hans Chief Financial Officer | Sale | −35,419 | $39.90 | $1.4M | 0 |
| 2021-02-24 | van Houte Hans Chief Financial Officer | Exercise or conversion · Employee Stock Option (right to buy) | −20,393 | 9,027 | ||
| 2021-02-24 | van Houte Hans Chief Financial Officer | Exercise or conversion · Employee Stock Option (right to buy) | −13,197 | 20,136 | ||
| 2021-02-24 | van Houte Hans Chief Financial Officer | Exercise or conversion · Employee Stock Option (right to buy) | −1,829 | 36,504 | ||
| 2021-02-22 | van Houte Hans Chief Financial Officer | Exercise or conversion | +1,417 | $0.84 | $1K | 1,417 |
| 2021-02-22 | van Houte Hans Chief Financial Officer | Exercise or conversion | +3,913 | $1.20 | $5K | 5,330 |
| 2021-02-22 | van Houte Hans Chief Financial Officer | Sale | −5,330 | $39.93 | $213K | 0 |
| 2021-02-22 | van Houte Hans Chief Financial Officer | Exercise or conversion · Employee Stock Option (right to buy) | −1,417 | 68,333 | ||
| 2021-02-22 | van Houte Hans Chief Financial Officer | Exercise or conversion · Employee Stock Option (right to buy) | −3,913 | 29,420 | ||
| 2021-02-18 | van Houte Hans Chief Financial Officer | Exercise or conversion | +13,583 | $0.84 | $11K | 13,583 |
Page 38 of 42 · 829 trades